POLYPEPTIDE GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29 CHF | -0.68% |
|
-1.69% | +65.53% |
| Mar. 12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| Mar. 12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
| Sales 2024 * | 349M 371M 338M | Sales 2025 * | 407M 433M 394M | Capitalization | 986M 1.05B 956M |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -12.78M -11.63M | Net income 2025 * | 14M 14.91M 13.57M | EV / Sales 2024 * | 3.1 x |
| Net Debt 2024 * | 93.91M 100M 91.03M | Net Debt 2025 * | 132M 140M 128M | EV / Sales 2025 * | 2.75 x |
| P/E ratio 2024 * |
-99.1
x | P/E ratio 2025 * |
63.8
x | Employees | 1,273 |
| Yield 2024 * |
-
| Yield 2025 * |
0.15% | Free-Float | 39.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyPeptide Group AG
More press releases
More news
| 1 day | -0.68% | ||
| 1 week | -1.69% | ||
| Current month | -4.29% | ||
| 1 month | +18.46% | ||
| 3 months | +101.11% | ||
| 6 months | +70.89% | ||
| Current year | +65.53% |
1 week
28.15
29.45
1 month
24.4831.14
Current year
14.1131.14
1 year
14.1131.14
3 years
14.11147.40
5 years
14.11147.40
10 years
14.11147.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 23-04-11 | |
| Chief Tech/Sci/R&D Officer | 52 | 11-12-31 | |
Jens Fricke
COO | Chief Operating Officer | 59 | 22-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 20-12-31 | |
Peter Wilden
CHM | Chairman | 67 | 21-03-31 |
Jane Anne Salik
BRD | Director/Board Member | 71 | 05-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +1.25% | - | |
| 0.00% | 26 M€ | -3.66% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 29 | -0.68% | 22,296 |
| 24-04-18 | 29.2 | +1.39% | 18,424 |
| 24-04-17 | 28.8 | -0.17% | 20,123 |
| 24-04-16 | 28.85 | -0.86% | 18,923 |
| 24-04-15 | 29.1 | +3.74% | 36,441 |
Delayed Quote Swiss Exchange, April 19, 2024 at 11:30 am EDT
More quotes
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
30.05
EUR
Average target price
22.24
EUR
Spread / Average Target
-26.00%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +65.53% | 1.06B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- PPGN Stock
